VYNE Therapeutics Announces Private Placement of $88 Million

Stock Information for VYNE Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About VYNE Therapeutics Inc.

VYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business Update
VYNE Therapeutics Provides Update on VYN202 Program
VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
VYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business Update
VYNE Therapeutics to Participate in March Investor Conferences
VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis
VYNE Therapeutics Completes Enrollment in Phase 2b Trial Evaluating VYN201 for the Treatment of Nonsegmental Vitiligo
VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.